miR-486-3p mediates hepatocellular carcinoma sorafenib resistance by targeting FGFR4 and EGFR

HCC is a common malignancy worldwide and surgery or reginal treatments are deemed insufficient for advanced-stage disease. Sorafenib is an inhibitor of many kinases and was shown to benefit advanced HCC patients. However, resistance emerges soon after initial treatment, limiting the clinical benefit...

Full description

Saved in:
Bibliographic Details
Published in:Cell Death Dis
Main Authors: Ji, Lin, Lin, Zhongjie, Wan, Zhe, Xia, Shunjie, Jiang, Shi, Cen, Dong, Cai, Liuxin, Xu, Junjie, Cai, Xiujun
Format: Artigo
Language:Inglês
Published: Nature Publishing Group UK 2020
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7170966/
https://ncbi.nlm.nih.gov/pubmed/32313144
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41419-020-2413-4
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items